new parp inhibitor drug approved to treat women with recurrent ovarian cancer
Published 7 years ago • 2.7K plays • Length 2:55Download video MP4
Download video MP3
Similar videos
-
4:13
treating ovarian cancers with parp inhibitors
-
1:32
parp inhibitors: reducing ovarian cancer recurrence risk
-
3:06
recurrent ovarian cancer: choosing a parp inhibitor
-
58:44
what’s new with parp inhibitors and ovarian cancer?
-
7:34
parp inhibition’s role in recurrent ovarian cancer
-
1:22
overcoming resistance to parp inhibition in ovarian cancer
-
0:59
the evolution of parp inhibitors in ovarian cancer
-
57:11
personalizing advanced ovarian cancer treatment with parp inhibitors and novel approaches
-
6:50
recurrent ovarian cancer: parp inhibitors compared
-
2:18
parp inhibition in recurrent ovarian cancer
-
3:30
2020 in review: olaparib & rucaparib, fda approval | ask a prostate expert, mark scholz, md
-
7:16
new options for recurrent ovarian cancer
-
6:20
parp inhibitors in recurrent ovarian cancer
-
5:32
parp inhibitor olaparib added to bevacizumab benefits women with ovarian cancer with and without...
-
6:39
difference among parp inhibitors for ovarian cancer
-
1:29
what to expect when going on a parp inhibitor for ovarian cancer
-
1:18
dr. backes on treatment selection with parp inhibitors in ovarian cancer
-
1:48
dr. westin on advances made with parp inhibitors in ovarian cancer
-
3:23
niraparib significantly improves outcomes for ovarian cancer patients